BioSpace News Archive

Avidity Biosciences, Inc. announced that on December 20, 2023, the Human Capital Management Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 7,100 shares of its common stock and 3,550 restricted stock units to two new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.

Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conference.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:00 a.m. Pacific Time, followed by a question and answer session.

Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study.

CooperCompanies, a leading global medical device company, will participate at the J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024.

MediciNova, Inc. today announced that an abstract regarding results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury has been selected for a poster presentation at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo to be held March 10 - 14, 2024 in Salt Lake City, Utah.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca’s WAINUA™ (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN.

Panbela Therapeutics, Inc. today announced it has entered into agreements with certain holders of its existing warrants exercisable for 2,556,000 shares of its common stock.

Cardio Diagnostics Holdings, Inc. today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director.

Marker Therapeutics, Inc. announced that the Company’s management team will participate in Biotech Showcase and present at the 19th Annual Non-Dilutive Funding Summit.